5Skubitz KM,Haddad PA. Padilaxel and pegylated-liposomal doxorttbicin are both active in angiosarcoma[ J]. Cancer, 2005, 104(2) :361- 366.
6D'Adamo DR, Anderson SE, Albritton K, et al. Phase ]I study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas[ J]. J Clin Oncol, 2005, 23(28) :7135-7142.
7Eisenhauer EA, Therasse P, Bctats J, et al. New response evaluation criteria in solid tumours : revised RECIST guideline ( version 1.1 ) [J]. Eur J Cancer, 2009, 45(2):228-247.
8Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors [ J ]. J Nucl Med, 2009, 50(Suppl 1 ) :122S-150S.
7Lydiatt WM,Shaha AR,Shah JP.Angiosarcoma of the head and neck.Am J Surg,1994,168:451-454.
8Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus I8rinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer.New Engl J Med,2004,350:2335-2342.
9Kabbinavar FF,Joseph Schulz J,McCleod M,et al.Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastastic colorectal cancer:results of a randomized phase Ⅱ trial.J Clin Oncol,2005,23:3697-3705.
10A. Maiorana,G. Collina,A. M. Cesinaro,R. A. Fano,V. Eusebi. Epithelioid angiosarcoma of the thyroid[J] 1996,Virchows Archiv(2-3):131～137
